THCT · As filed with the SEC
THC Therapeutics balance sheet, by quarter
The statement as THC Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD
| USD | Q4 FY24 Jul 31, 2024 | Q3 FY24 Apr 30, 2024 | Q2 FY24 Jan 31, 2024 | Q1 FY24 Oct 31, 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash and cash equivalents | — | 849 | 3,511 | 10 |
| Cash | 35 | — | — | — |
| Prepaid Expenses | 0 | 0 | 0 | 0 |
| Inventory | — | — | — | 0 |
| Total current assets | 35 | 849 | 3,511 | 10 |
| Intangible Assets | — | — | 11,308 | 11,659 |
| Intangible Assets | 10,613 | 10,964 | — | — |
| Total assets | 10,648 | 11,813 | 14,819 | 11,669 |
| Current liabilities | ||||
| Accounts Payable | 1,319,294 | 2,105,922 | 2,067,293 | 2,008,793 |
| Accrued expenses - related party | — | 6,874 | 6,874 | 6,032 |
| Accounts payable and accrued liabilities - related party | 1,001,001 | — | — | — |
| Advances from related parties | 145,106 | 145,106 | 59,626 | 59,917 |
| Short-Term Debt | 25,000 | 25,000 | 25,000 | 25,000 |
| Short-Term Debt | 576,028 | 576,028 | 576,028 | 576,028 |
| Convertible notes payable- related party | — | 130,761 | 130,761 | 130,761 |
| Convertible notes payable, related party | 130,761 | — | — | — |
| Other Non-Operating Current Liabilities | 615,013 | 441,953 | 944,610 | 477,456 |
| Total current liabilities | 3,812,203 | 3,431,644 | 3,810,192 | 3,283,987 |
| Total liabilities | 3,812,203 | 3,431,644 | 3,810,192 | 3,283,987 |
| Commitments and Contingencies (See note 10) | 0 | 100,000 | 100,000 | 100,000 |
| Stockholders' deficit | ||||
| Series A Preferred Stock | 826 | 826 | 226 | 226 |
| Series B Preferred Stock | 0 | 0 | 0 | 0 |
| Series C Preferred Stock | 0 | 0 | 0 | 0 |
| Total Stockholders' Equity | 40,266 | 40,266 | 32,746 | 32,746 |
| Treasury stock, at cost, 1,400,0000 shares as of April 30, 2024 and July 31, 2023, respectively. | — | (97,500) | — | — |
| Stock payable | — | 486,228 | 752,228 | 752,228 |
| Stock receivable | — | (6,902,000) | (6,902,000) | (6,902,000) |
| Treasury stock | (97,500) | — | — | — |
| Stock payable | 486,228 | — | — | — |
| Stock receivable | (6,902,000) | — | — | — |
| Additional Paid-In Capital | 41,906,132 | 41,906,132 | 41,279,832 | 41,230,912 |
| Retained Earnings | (39,235,507) | (38,953,783) | (39,058,405) | (38,486,430) |
| Total stockholders' deficit | (3,801,555) | (3,519,831) | (3,895,373) | (3,372,318) |
| Total liabilities and stockholders' deficit | 10,648 | 11,813 | 14,819 | 11,669 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.